Alpha 2.0
Login Register
» Authors » E D Gomperts

E D Gomperts

Explore the profile of E D Gomperts including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 93
Citations 499
Followers 0
Related Specialties
Hematology
General Medicine
Pediatrics
Top 10 Co-Authors
S M Donfield
A D Shapiro
S S Zail
J Metz
J Hockley
M Feesey
M Lee
G L Bray
B L Evatt
M W Hilgartner
Published In
Haemophilia
S Afr Med J
Br J Haematol
Thromb Haemost
Thromb Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients
Collins P, Quon D, Makris M, Chowdary P, Kempton C, Apte S, et al.
Haemophilia . 2017 Aug; 24(1):104-112. PMID: 28833808
Introduction: Trenonacog alfa (IB1001) is a recombinant factor IX (rFIX) manufactured in Chinese hamster ovary (CHO) cells. IB1001 was evaluated in a multicentre clinical trial with haemophilia B patients. Aim:...
2.
A multicenter study of recombinant factor VIII (Recombinate(TM) ) in previously treated patients with hemophilia A
White G, Courter S, Bray G, Lee M, Gomperts E
Haemophilia . 2016 May; 3(3):232. PMID: 27214819
No abstract available.
3.
Long-term surveillance for human anti-murine antibodies of a group of haemophiliacs treated only with immunoaffinity-purified FVIII concentrates
Brackmann H, Gomperts E, Courter S, Vidor A, OBrien S, Oldenburg J
Haemophilia . 2016 May; 1(2):111-4. PMID: 27214318
An immunoaffinity purified, solvent/detergent virally inactivated factor VIII (FVIII) concentrate (Hemofil® M) has been in clinical use in persons with haemophilia A since March 1987 and under clinical trial prior...
4.
F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
Schwarz J, Astermark J, Menius E, Carrington M, Donfield S, Gomperts E, et al.
Haemophilia . 2012 Sep; 19(1):113-8. PMID: 22958194
Ancestral background, specifically African descent, confers higher risk for development of inhibitory antibodies to factor VIII (FVIII) in haemophilia A. It has been suggested that differences in the distribution of...
5.
von Willebrand factor: what is its role in the immune response in haemophilia?
Kaveri S, Mannucci P, Kurth M, Ewing N, Kessler C, Nugent D, et al.
Haemophilia . 2010 Jun; 17(1):e235-8. PMID: 20546026
No abstract available.
6.
Potency and mass of factor VIII in FVIII products
Butenas S, Parhami-Seren B, Gissel M, Gomperts E, Fass D, Mann K
Haemophilia . 2008 Aug; 15(1):63-72. PMID: 18691375
Several factor (F) VIII products of different origin and structure are being used for haemophilia A treatment worldwide. The assessment of FVIII concentration in these products is done using activity...
7.
The parachute must be properly folded
Donfield S, Shapiro A, Gomperts E, Lynn H, Usner D
J Thromb Haemost . 2006 Nov; 5(3):646-7. PMID: 17092299
No abstract available.
8.
The need for previously untreated patient population studies in understanding the development of factor VIII inhibitors
Gomperts E
Haemophilia . 2006 Nov; 12(6):573-8. PMID: 17083506
The presence of inhibitory antibodies to factor VIII (FVIII) remains one of the most serious complications of haemophilia therapy. Accordingly, understanding risk factors that may contribute to inhibitor developments in...
9.
Haemophilia Inhibitor Genetics Study - evaluation of a model for studies of complex diseases using linkage and association methods
Berntorp E, Astermark J, Donfield S, Nelson G, Oldenburg J, Shapiro A, et al.
Haemophilia . 2005 Jul; 11(4):427-9. PMID: 16011603
No abstract available.
10.
Haemophilia-related morbidity and quality-of-life
Donfield S, Shapiro A, Gomperts E, Lynn H
Haemophilia . 2005 Jul; 11(4):418. PMID: 16011599
No abstract available.